Home > Insider Trading > Filing (0001209191-18-063384)

Filing Details

Accession Number:: 0001209191-18-063384
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-12-18 21:48:48
Reporting Period:: 2018-12-17

Accepted Time:: 2018-12-18 21:48:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1370053	Anaptysbio Inc	ANAB	Pharmaceutical Preparations (2834)	203828755

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1654500	Marco Londei	C/O Anaptysbio, Inc. 10421 Pacific Center Court, Suite 200 San Diego CA 92121	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-12-17	8,048	$0.70	152,925	No	4	M	Direct
Common Stock	Acquisiton	2018-12-17	22,000	$6.93	174,925	No	4	M	Direct
Common Stock	Disposition	2018-12-17	12,120	$65.36	162,805	No	4	S	Direct
Common Stock	Disposition	2018-12-17	3,185	$66.38	159,620	No	4	S	Direct
Common Stock	Disposition	2018-12-17	8,002	$67.57	151,618	No	4	S	Direct
Common Stock	Disposition	2018-12-17	6,741	$68.47	144,877	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-12-17	8,048	$0.00	8,048	$0.70
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-12-17	22,000	$0.00	22,000	$6.93

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,060		2024-10-27	No	4	M	Direct
70,223		2025-08-13	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $68.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 to $68.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining options to purchase 80,283 shares of common stock as set forth in Table II, the Reporting Person also holds (i) 144,877 shares of common stock held directly; and (ii) additional options to purchase up to an aggregate of 138,000 shares of common stock, which options vest according to their terms.